Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...
T he most unique prospect in recent memory to come through the NFL Draft is Colorado's Travis Hunter. Why? Well, he just ...
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
The Economic Blackout, sponsored by The People’s Union USA, takes place today, Feb. 28. The peaceful protest is an attempt to disrupt corporations that have dropped their diversity, equity, and ...
An international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The ...
Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...